Cost-effectiveness of Nivolumab-Ipilimumab Combination Therapy for the Treatment of Advanced Non-Small Cell Lung Cancer.

ABSTRACT:

Importance

Treatment with nivolumab-ipilimumab combination therapy was found to improve overall survival compared with chemotherapy among patients with advanced non-small cell lung cancer (NSCLC) in the CheckMate 227 clinical trial. However, these drugs are substantially more expensive than chemotherapy and, given the high incidence of advanced NSCLC, the incorporation of dual immune checkpoint inhibitors into the standard of care could have substantial economic consequences.

Objective

To assess whether nivolumab-ipilimumab combination therapy is a cost-effective first-line treatment for patients with advanced NSCLC.

Design, setting, and participants

This economic evaluation designed a Markov model to compare the cost-effectiveness of nivolumab-ipilimumab combination

SUBMITTER: Courtney PT 

PROVIDER: S-EPMC8094011 | biostudies-literature | 2021 May

REPOSITORIES: biostudies-literature